Abstract
Studies of the genetics of Alzheimer’s disease (AD) have largely focused on single nucleotide variants and short insertions/deletions. However, most of the disease heritability has yet to be uncovered, suggesting that there is substantial genetic risk conferred by other forms of genetic variation. There are over one million short tandem repeats (STRs) in the genome, and their link to AD risk has not been assessed. As pathogenic expansions of STR cause over 30 neurologic diseases, it is important to ascertain whether STRs may also be implicated in AD risk. Here, we genotyped 321,742 polymorphic STR tracts genome-wide using PCR-free whole genome sequencing data from 2,981 individuals (1,489 AD case and 1,492 control individuals). We implemented an approach to identify STR expansions as STRs with tract lengths that are outliers from the population. We then tested for differences in aggregate burden of expansions in case versus control individuals. AD patients had a 1.19-fold increase of STR expansions compared to healthy elderly controls (p=8.27×10−3, two-sided Mann Whitney test). Individuals carrying > 30 STR expansions had 3.62-fold higher odds of having AD and had more severe AD neuropathology. AD STR expansions were highly enriched within active promoters in post-mortem hippocampal brain tissues and particularly within SINE-VNTR-Alu (SVA) retrotransposons. Together, these results demonstrate that expanded STRs within active promoter regions of the genome promote risk of AD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work is supported by NIH National Institute of Neurologic Disorders and Stroke (R25 NS065745 to MHG), University of Pennsylvania Christopher Clark Scholars Award (to MHG), NIH National Institute on Aging (RF1-AG074328, P30-AG072979, U54-AG052427, and U24-AG041689 to WPL), NIH National Institute of Mental Health (1R01MH120269 to JEPC), NSF CAREER Award (CBE-1943945 to JEPC), NSF EFRI Award (EFMA1933400 to JEPC), and Chan Zuckerberg Initiative Neurodegenerative Disease Pairs Awards (2020-221479-5022 and DAF2022-250430 to JEPC).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The National Institute on Aging Alzheimer's Disease Data Storage Site (NIAGADS) provided authorized access to the genetic and phenotype data for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data analyzed in this study is subject to the following licenses/restrictions: Data is accessible from NIAGADS DSS via qualified access. Formal requests to access these datasets can be submitted to NIAGADS DSS: https://dss.niagads.org/.
